Clinical Study Distribution Is Not Ordinary Commercial Fulfillment

A clinical study shipment may look operationally similar to a commercial order, but the governing logic is different. Commercial fulfillment is designed to satisfy a customer order. Clinical study distribution must ensure that the correct investigational device reaches an authorized site for use under the applicable protocol and investigator controls, with a complete accountability trail.

Authorization Must Be Confirmed Before Release

Before release, the distribution process should confirm that the study, site, investigator and shipment are authorized; that the site is activated under the sponsor’s procedures; and that the device configuration, quantity, labeling, storage conditions and destination match the study requirements.

A purchase order or request from site personnel is not, by itself, sufficient authority to ship. The release decision should follow a study-specific authorization matrix rather than an ordinary sales-order workflow.

Accountability Continues After Delivery

FDA regulations require sponsors to maintain shipment and disposition records, including the consignee, device type and quantity, shipment date, and batch number or code mark.

Investigators must maintain complete, current and accurate records of device receipt, use and disposition, restrict use to subjects under their supervision, and return or dispose of remaining devices as directed.

The distributor’s records must therefore support reconciliation among inventory released, inventory received, devices used, devices returned, and any losses, damage or other exceptions.

Exceptions Require Predefined Escalation

A temperature excursion, damaged package, incorrect delivery, Customs delay, missing unit, changed site address, cancelled procedure, or request to move inventory should not be resolved through routine customer-service judgment.

The sponsor or its authorized delegate may need to determine whether the device remains suitable, whether replacement is permitted, how the event is documented, and whether study records or other stakeholders must be updated.

Site Rebalancing Is a Controlled Study Activity

When one site has excess unused inventory and another has an immediate need, the sponsor may authorize transfer to the receiving site or return through a central reserve. This is not an informal site-to-site shipment.

Rebalancing should confirm that the receiving site is authorized, preserve storage and transport conditions, capture serial, lot, batch and expiration information as applicable, document chain of custody, and update accountability records at every location.

Maintain Separation From Commercial Distribution

MDD Studies provides a study-specific distribution structure rather than treating investigational devices as ordinary commercial inventory.

Services can include controlled study setup, authorization checks, central-reserve management, temperature-controlled shipment, site support, returns, exception handling and sponsor-directed site rebalancing.

Where needed, these activities can also be coordinated with MDD Options for import and U.S. regulatory roles, while maintaining a clear separation between clinical-study inventory and commercial distribution.